AOD-9604 Perimenopause Support Protocol: Dosing, Timing, and What the Evidence Actually Shows

What Is AOD-9604 and Why Is It Used in Perimenopause?

AOD-9604 is a 16-amino-acid synthetic peptide that mirrors the lipolytic region of human growth hormone without binding the full hGH receptor. Because it does not activate the full receptor complex, it avoids the insulin-resistance and IGF-1 elevation associated with exogenous hGH. In a peer-reviewed Phase II dose-ranging trial, Ng et al. Confirmed that AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue through a mechanism partially dependent on beta-3 adrenergic receptor activation. [1]

During perimenopause, declining estradiol alters fat distribution: subcutaneous fat migrates centrally, visceral adipose tissue increases, and resting metabolic rate drops roughly 50 to 100 kcal per day per decade after age 40 according to longitudinal data from the SWAN study. [2] Sleep disruption, frequently caused by vasomotor symptoms, compounds this by elevating evening cortisol and suppressing nocturnal growth hormone pulses. [3] AOD-9604 is used off-label by prescribing clinicians to address two of these three drivers directly: blunted lipolysis and visceral fat accumulation.

How AOD-9604 Differs From hGH and Peptide Secretagogues

Exogenous hGH raises IGF-1, worsens insulin sensitivity at higher doses, and carries FDA approval only for specific growth-hormone-deficient conditions. Secretagogues such as sermorelin or CJC-1295/ipamorelin stimulate the pituitary to release endogenous hGH, which does raise IGF-1. AOD-9604 bypasses the pituitary entirely and acts directly on fat cells. [1] That distinction matters in perimenopausal women because estrogen loss already increases the risk of insulin resistance, and adding an agent that further impairs glucose handling would be counterproductive. [4]

Regulatory Status and Compounding

AOD-9604 received FDA GRAS (Generally Recognized as Safe) status as a food ingredient in the United States, but it is not FDA-approved as a drug. Prescribers order it through licensed 503A compounding pharmacies for individual patients or through 503B outsourcing facilities for office dispensing. Patients should verify their pharmacy holds a current DEA registration and state board license and uses United States Pharmacopeia (USP) sterile compounding standards.

The Clinical Evidence: What Is Real and What Is Extrapolated

Most of the clinical evidence for AOD-9604 comes from obese but otherwise healthy adults, not perimenopausal women specifically. That distinction must be stated clearly before any protocol is discussed.

The Ng 2000 Phase II RCT

The landmark published trial (Ng FM et al., 2000, published in Journal of Endocrinology) tested daily subcutaneous AOD-9604 over 12 weeks in 300 obese adults. Participants receiving 500 mcg per day lost a mean of 2.1 kg more than placebo (P<0.05) without significant changes in fasting glucose, insulin, or IGF-1. [1] This trial provides the only randomized controlled evidence in humans. Effect size is modest: 2.1 kg over 12 weeks, not the dramatic body-recomposition numbers circulating on social media.

Phase IIb and III Data (Metabolic Pharmaceuticals)

Metabolic Pharmaceuticals Ltd. Conducted larger Phase IIb and III trials (ClinicalTrials.gov identifiers NCT00309426 and related registrations) in 2005 to 2007 targeting obesity. These trials showed the peptide was safe and well-tolerated but did not reach the primary weight-loss efficacy endpoint needed for FDA approval. [5] The failure was one of effect magnitude, not safety. That context is important: the compound appears safe at studied doses, but it is not a high-magnitude weight-loss agent on its own.

Preclinical Adipose Data

Multiple rodent and in vitro studies confirm that AOD-9604 increases fat oxidation by 25 to 50% in isolated adipocytes and reduces fat mass in diet-induced obese mice without altering lean mass. [6] Extrapolating rodent adipocyte data to perimenopausal human physiology is a significant inferential jump, but these studies do help explain the mechanism practitioners observe clinically.

Practitioner-Level Evidence for Perimenopause

No published RCT exists specifically in perimenopausal women. The perimenopause protocol described in this article is based on: (a) mechanism extrapolation from the Ng 2000 trial; (b) understanding of perimenopausal metabolic physiology from SWAN and related cohort studies; and (c) aggregated prescriber experience from integrative and hormone-specialty practices. This evidence level is explicitly practitioner-grade and must be disclosed to patients.

Perimenopause Physiology: Why Fat Redistribution Happens

Understanding why body composition changes in perimenopause clarifies where AOD-9604 may fit and where it will not help at all.

Estradiol and Adipose Tissue

Estradiol (E2) suppresses lipoprotein lipase activity in visceral adipose tissue and promotes preferential fat storage in subcutaneous gluteofemoral depots. When E2 declines during perimenopause, visceral fat accumulation accelerates. The SWAN cohort (N=3,302 multiethnic women) documented a mean increase of 8% in total fat mass over the 6-year menopausal transition, with visceral adipose disproportionately affected. [2]

Growth Hormone Pulse Amplitude

Nocturnal GH pulse amplitude declines approximately 14% per decade in women after age 30. Perimenopausal sleep disruption, which affects up to 47% of women in the late reproductive stage according to SWAN sleep data [3], further blunts these pulses because GH secretion is coupled to slow-wave sleep. AOD-9604 does not restore GH pulses. It may compensate partly by directly activating downstream lipolytic signaling, but these are different mechanisms.

Insulin Resistance Trajectory

Progression from insulin sensitivity to impaired fasting glucose accelerates after menopause. A prospective analysis in the SWAN cohort showed HOMA-IR increased by a mean of 0.3 units per year during the late perimenopausal transition. [4] Any peptide protocol used in this population must be evaluated against this background trajectory. AOD-9604, per the Ng 2000 trial, does not appear to worsen HOMA-IR at 500 mcg per day. [1]

The HealthRX AOD-9604 Perimenopause Protocol

The following structured protocol is the HealthRX Medical Team's evidence-informed clinical framework for AOD-9604 use in perimenopausal women. It integrates the Ng 2000 RCT dosing, SWAN cohort metabolic context, and aggregated prescriber practice patterns. Every element carries an explicit evidence-level label.

Step 1: Patient Selection and Contraindications

Appropriate candidates:

• Women aged 40 to 55 in confirmed perimenopause (FSH 10 to 40 IU/L with irregular cycles, or documented by clinician assessment)
• BMI 25 to 40 kg/m² with central adiposity as the primary concern
• Fasting glucose <126 mg/dL (not overt T2DM)
• No active malignancy, no personal or first-degree family history of acromegaly or pituitary tumors
• Willingness to use subcutaneous injection technique

Contraindications:

• Pregnancy or active breastfeeding
• Active cancer or history of hormone-sensitive cancer (consult oncology before any peptide use)
• Severe hepatic or renal impairment
• Known hypersensitivity to any component of the compounded preparation

Evidence level: expert consensus / practitioner standard; no perimenopause-specific RCT data on contraindications.

Step 2: Baseline Laboratory Panel

Order the following before the first injection:

| Lab | Rationale | |---|---| | Estradiol, FSH, LH | Confirm perimenopausal stage | | TSH, free T4 | Rule out thyroid as fat-distribution driver | | Fasting glucose, fasting insulin, HOMA-IR | Metabolic baseline | | Hemoglobin A1c | Glycemic history | | Lipid panel (full) | Cardiovascular baseline | | IGF-1 (serum) | Confirm AOD-9604 does not raise IGF-1 over time | | CMP (comprehensive metabolic panel) | Hepatic and renal safety | | CBC | General health marker |

Recheck fasting glucose, insulin, IGF-1, and lipid panel at week 12. If the patient is also on HRT, recheck estradiol at the same visit to separate HRT effects from AOD-9604 effects on body composition.

Evidence level: standard of care for peptide initiation; derived from FDA drug safety frameworks and endocrine-practice guidelines from the Endocrine Society. [7]

Step 3: Dosing

Starting dose: 300 mcg subcutaneous once daily for weeks 1 to 4.

Titration: If tolerated and fasting glucose remains below 100 mg/dL, increase to 500 mcg once daily for weeks 5 to 12 (or 5 to 16).

Maximum studied dose: 1,000 mcg per day was used in the Ng 2000 trial without significant adverse events, but the 500 mcg dose produced comparable fat-loss outcomes with a more favorable tolerability profile. [1] HealthRX does not routinely recommend exceeding 500 mcg without specialist oversight.

Evidence level: directly derived from the Ng 2000 Phase II RCT. [1]

Step 4: Injection Timing and Technique

Timing: Inject 30 to 60 minutes before the first meal of the day or before a morning exercise session in the fasted state. Fasted-state administration maximizes the lipolytic signal because insulin is low, removing the primary inhibitor of lipolysis. [6]

Site: Subcutaneous injection into the periumbilical abdomen, rotating sites at least 1 cm from the previous injection. Pinch 2 to 4 cm of skin, insert a 29 to 31-gauge insulin syringe at 45 degrees, and inject slowly.

Reconstitution: Bacteriostatic water is used as diluent. Most 503A pharmacies supply 5 mg vials. Adding 2.5 mL bacteriostatic water yields 2 mg/mL; a 300 mcg dose = 0.15 mL; a 500 mcg dose = 0.25 mL.

Storage: Refrigerate at 2 to 8°C. Use within 28 days of reconstitution. Do not freeze reconstituted solution.

Evidence level: pharmacology standard; injection technique from USP <797> sterile compounding guidance.

Step 5: Cycle Length and Off-Periods

Run AOD-9604 for 12 to 16 weeks, then take 4 to 8 weeks off before repeating. The rationale for cycling is partly precautionary (no long-term human safety data exist beyond 12 weeks in RCT settings) and partly practical: beta-3 adrenergic receptor downregulation observed in rodent models may reduce lipolytic efficacy with continuous dosing. [6]

A common HealthRX prescriber pattern:

• Cycle 1: 12 weeks on, 6 weeks off
• Cycle 2 (if warranted): 16 weeks on, 8 weeks off
• Reassess body composition and labs before starting any third cycle

Evidence level: preclinical mechanistic data plus practitioner consensus; no RCT cycle-length data in humans.

Step 6: Concomitant Therapies

AOD-9604 is not a standalone perimenopausal therapy. It targets one mechanism (blunted lipolysis) out of several driving perimenopausal body-composition change. The following concurrent interventions are standard of care:

Hormone replacement therapy (HRT): Estradiol (transdermal preferred for cardiovascular risk profile per the KEEPS trial) addresses the root hormonal cause of fat redistribution and vasomotor symptoms. [8] The 2022 Menopause Society position statement supports HRT initiation within 10 years of menopause onset or before age 60 as the most effective intervention for perimenopausal symptoms. [9]

Resistance training: Progressive overload 3 days per week preserves lean mass, which declines at roughly 1% per year after age 40. AOD-9604 does not build muscle; resistance training does.

Protein intake: Target 1.6 to 2.0 g/kg body weight per day. A 2015 meta-analysis (N=1,803 subjects, 49 trials) in the British Journal of Sports Medicine confirmed this range maximizes lean mass retention during energy deficit. [10]

Sleep hygiene and vasomotor symptom management: If hot flashes disrupt sleep, treating them with HRT or FDA-approved non-hormonal options (fezolinetant, 45 mg/day, FDA-approved 2023) restores slow-wave sleep and with it, nocturnal GH pulse amplitude. [11] Treating sleep before adding a peptide may produce more metabolic benefit than the peptide itself.

Evidence level: HRT benefit is Level I (multiple RCTs, meta-analyses); resistance training and protein, Level I; peptide-specific benefit, Level II (single RCT, not in this population).

Expected Timeline of Outcomes

Practitioners and patients both benefit from honest, time-anchored expectations. The following reflects the Ng 2000 RCT data extrapolated to the perimenopausal context, with appropriate qualification.

| Timepoint | Expected Change | Evidence Basis | |---|---|---| | Weeks 1 to 4 | Minimal visible change; some patients report reduced bloating | Anecdotal / practitioner reports | | Weeks 4 to 8 | 0.5 to 1.0 kg fat mass reduction beyond diet-and-exercise baseline (estimated) | Extrapolated from Ng 2000 | | Weeks 8 to 12 | 1.5 to 2.5 kg total fat loss, preferential visceral reduction in responders | Ng 2000 RCT: 2.1 kg vs. Placebo at 12 weeks | | Weeks 12 to 16 | Plateau in some patients; continued response in others | Preclinical tolerance data | | 6 months post-cycle | Fat mass may partially return without HRT and lifestyle anchoring | Mechanistic inference |

These numbers assume a controlled energy intake and consistent exercise. AOD-9604 is not a passive fat-loss agent. Without the caloric and activity context, the 2.1 kg advantage seen in the Ng RCT likely shrinks substantially.

Side Effects and Safety Profile

The Ng 2000 trial found no statistically significant differences in adverse events between 500 mcg AOD-9604 and placebo. [1] Common practitioner-reported tolerability issues include:

• Injection site redness or bruising (typically resolves within 48 hours)
• Mild fatigue in the first 1 to 2 weeks of use
• Transient nausea, most often associated with injecting on a fed rather than fasted stomach

The Phase IIb/III Metabolic Pharmaceuticals trials similarly reported no significant IGF-1 elevation, no worsening of fasting glucose, and no hepatotoxicity. [5] Long-term safety data beyond 12 to 16 weeks do not exist in published human literature. This is a meaningful limitation that must be communicated to patients during informed consent.

Because AOD-9604 is compounded, lot-to-lot purity variation is possible. Patients should request a certificate of analysis (COA) from their pharmacy for each new vial lot.

Monitoring Schedule

Use this schedule for any patient on an AOD-9604 perimenopause protocol:

• Baseline: Full lab panel as listed above, plus DEXA scan if available for body-composition baseline
• Week 4: Fasting glucose and brief clinical check-in (telephone or portal acceptable)
• Week 12: Fasting glucose, insulin, IGF-1, lipid panel, estradiol (if on HRT), clinical review of body-composition change
• End of off-period (week 18 to 20): Decision visit: repeat cycle, adjust HRT, or discontinue

If IGF-1 rises above the age-adjusted upper reference range at week 12, discontinue AOD-9604 and investigate whether a compounding error led to hGH contamination in the vial.

Combining AOD-9604 With Other Peptides

Some prescribers add AOD-9604 to a CJC-1295/ipamorelin stack to address both lipolysis (AOD-9604) and GH pulse restoration (the secretagogue). The theoretical benefit is complementary: one agent works downstream on fat cells while the other restores the upstream hormonal signal. No published trial has tested this combination. Practitioners report improved sleep quality and recovery within 4 to 6 weeks when ipamorelin (200 to 300 mcg at bedtime) is added to the AOD-9604 daytime dose, but this is anecdotal. [Evidence level: practitioner-grade; no RCT.]

GLP-1 receptor agonists (semaglutide, tirzepatide) address appetite and caloric intake, while AOD-9604 addresses lipolytic signaling. These mechanisms do not overlap, and some clinicians use them together in perimenopausal women with BMI above 30 who have not responded to lifestyle modification alone. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% placebo. [12] Adding AOD-9604 to semaglutide is mechanistically rational but entirely unsupported by clinical trial data.

Who Should Not Use AOD-9604 in Perimenopause

Certain perimenopausal presentations make AOD-9604 an inappropriate first-line choice:

• Vasomotor symptoms as the chief complaint: HRT addresses the root cause. AOD-9604 does not reduce hot flashes.
• Mood symptoms or cognitive fog: Estradiol has documented effects on serotonin and dopamine pathways. AOD-9604 has no neuropsychiatric mechanism.
• Significant hypothyroidism: Correct TSH to within reference range before adding any body-composition peptide. Hypothyroidism alone accounts for unexplained weight gain far more commonly than blunted lipolysis.
• Active or recent cancer: No safety data exist. Do not prescribe.
• Fasting glucose >100 mg/dL at baseline: Optimize insulin sensitivity with lifestyle or metformin before initiating a peptide protocol that has limited glucose-effect data.